| Prev Close | 46.85 |
| Open | 48.41 |
| Day Low/High | 47.56 / 50.73 |
| 52 Wk Low/High | 7.42 / 55.38 |
| Volume | 1.97M |
Invitae Corp. (NVTA)
50.06
3.21
6.85
NYSE
| Exchange | NYSE |
| Shares Outstanding | 176.70B |
| Market Cap | 8.28B |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Here Are 3 Covid-19 Testing Stocks to Watch
A lot of these stocks have been beneficiaries of the additional focus on the need for testing.
I'm Dipping a Toe in Invitae
A close above $18 would go a long way towards making breakout buyers feel better.
4 ETFs on the Cutting Edge: Data, Genomics, Robotics and Fintech
These ARK Funds family funds are focused on new opportunities and investment themes.
Two More Biotechs to Consider
The market has weakened just a tad since our last update but remains directionless. The Energy sector continues to be the weakest of the 11 S&P sectors this year and the Energy Select Sector SPDR is off another 1% today and that is with oil prices b...
It Is the 'Flow' of the Action That Matters Most Now
What is most notable about this market action is that it never seems to fully discount the optimism about a China trade deal.
Investing in Small Biotechs? Check Out the CFO First
They're the most important executive at most small developmental or early commercialization concerns.
Yes, the Market Hates Uncertainty
If the macro issues calm down there should be some good trade opportunities.
A Weak Bounce Continues as Stock Picking Heats Up
The market action is creating some mis-pricing in individual stocks. But if the market stays under pressure then stock picking will remain difficult.
Swinging for the Small-Cap Biotech Fences Requires Accepting Strikeouts
Striking out is painful, but is not as impactful as missing out on the next potential home run because you're still brooding about whiffing on your last investment.
IBM and Netflix Go Separate Ways in Nervous Trading
I don't expect to see the bears and shorts press too hard right now but there isn't going to be much upside momentum.
These Intriguing ETFs Are on the Cutting Edge of Disruptive Technologies
Ark Invest has developed a series of specialized exchange-traded funds that own shares in companies involved in 'disruptive innovation.'
Electric Car Stocks Get a Charge as Pockets of Momentum Develop
When the indices aren't offering much opportunity money flows into individual speculative names.
3 Small Biotechs to Watch as Earnings Season Winds Down
One already is up nicely on its results, while the other two should issue reports of interest in the next few days.
Here Are 3 Small-Cap Names for Biotech Investors to Consider
We look at a slightly riskier part of the sector...that should be able to reach profitability with little to no additional funding needs.
Consider These Diagnostic Testing Firms
Diagnostic firms can have an advantage of recurring revenue streams.
Names to Watch Amid Biotech's Nascent Rally
Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.
3 Small Biotechs Turn on the Revenue Jets
BioDelivery Sciences, Neos Therapeutics and Invitae Corp. are delivering big increases in sales.
3 of My Favorite Medical Diagnostic Plays
These equities have been in rally mode since April.
3 Favorite Biotech Stocks for the Second Quarter
Your questions are answered in our latest addition of the biotech mailbag.
Lackluster Market on Tons of Earnings
Some good discussions today on the Daily Diary. Look forward to continuing the conversation tomorrow as we look to wrap up a solid week for equities. Market was lackluster today but had a ton of earnings reports to take into account. Not to mention ...
Shark Bites: Traders Could Trip on This Market Bounce
V-shaped moves are more common than they used to be.
Three Health-Care Growth Plays
Eagle Pharmaceuticals, Invitae and Celgene should do well this year and are attractively priced.
Invitae Inviting as Undervalued Growth Play
The rapidly growing genetic testing concern is executing its growth plan marvelously.
Biotech, Health Care Likely to Drive IPOs at NYSE in Second Half
Garvis Toler, head of global capital markets at the NYSE, reviews the landscape of IPOs during the first half of 2015 and previews what's in store for the second half.
